Microcap Ledger Jasper Therapeutics, Inc. $JSPR
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Redwood City, CA
- Fiscal year end
- December 31
- Shares outstanding
- 33,274,561 [10-Q 2026-08-14]
What the company doesAI summary of filing
Jasper Therapeutics is a clinical-stage biotechnology company developing therapeutics targeting mast cell-driven diseases, including Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block the SCF/KIT pathway to deplete mast cells. Jasper is currently conducting Phase 1b/2a clinical trials in chronic urticarias and a Phase 1b proof-of-concept study in asthma; the company is pre-revenue and has discontinued its historical stem cell transplant conditioning programs to focus exclusively on mast cell diseases. Briquilimab is exclusively licensed from Amgen for development and commercialization worldwide. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$3.93M | −$21.47M | $7.31M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$75.80 | −$77.16M | $28.69M | [DEF 14A 2026-06-15] |
| FY ended Dec 2024 | — | −$71.30M | −$62.60M | $71.64M | [DEF 14A 2026-06-15] |
- Quarterly cash burn
- −$10.73M
- Cash runway Estimate
- ~2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2023-10-31 | 111,575,261 | [10-Q 2023-11-09] |
| 2025-02-25 | 15,022,122 | [10-K 2025-02-28] |
| 2025-05-08 | 15,022,122 | [10-Q 2025-05-12] |
| 2025-08-11 | 16,253,332 | [10-Q 2025-08-13] |
| 2025-11-06 | 27,984,039 | [10-Q 2025-11-10] |
| 2026-03-25 | 27,996,819 | [10-K/A 2026-04-30] |
| 2026-05-11 | 27,996,819 | [10-Q 2026-05-14] |
| 2026-08-10 | 33,274,561 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2025-03-19; declared effective 2025-03-26 [S-3 2025-03-19]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-06-09. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-06-09 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-06-09] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | PRE 14A | Proxy statement |
| 2026-10-07 | 8-K | Other events |
| 2026-10-05 | 8-K | Shareholder vote results |
| 2026-09-28 | 8-K | Director or officer change |
| 2026-09-04 | DEF 14A | Proxy statement |
| 2026-08-26 | 8-K | Material agreement entered |
| 2026-08-24 | PRE 14A | Proxy statement |
| 2026-08-17 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 8-K | Results of operations |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-03 | 8-K | Shareholder vote results |
| 2026-07-31 | 8-K | Other events |
Alerts for $JSPR
Email me when Jasper Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.